Structures by: Reymond J. L.
Total: 18
C31H29NO7
C31H29NO7
Organic letters (2004) 6, 3 397-400
a=9.5168(14)Å b=10.0609(14)Å c=14.103(2)Å
α=77.431(12)° β=77.178(12)° γ=79.479(12)°
C30H27NO8
C30H27NO8
Organic letters (2004) 6, 3 397-400
a=8.7426(8)Å b=10.6484(9)Å c=14.4952(13)Å
α=96.122(7)° β=99.555(7)° γ=104.529(7)°
C28H23N3O4
C28H23N3O4
Organic letters (2003) 5, 24 4693-4696
a=10.1436(11)Å b=8.0346(6)Å c=29.122(4)Å
α=90.00° β=96.601(10)° γ=90.00°
C31H28N4O7
C31H28N4O7
Organic letters (2003) 5, 24 4693-4696
a=10.2388(8)Å b=11.3897(10)Å c=12.7626(10)Å
α=85.466(10)° β=73.957(9)° γ=76.834(10)°
C37H56N8O9
C37H56N8O9
Chem. Sci. (2015) 6, 10 5473
a=9.2715(4)Å b=36.7577(15)Å c=11.3129(5)Å
α=90° β=90.098(4)° γ=90°
C39H64N8O12
C39H64N8O12
Chem. Sci. (2015) 6, 10 5473
a=17.7309(7)Å b=9.6245(3)Å c=26.2360(10)Å
α=90° β=107.755(4)° γ=90°
C39H64N8O12
C39H64N8O12
Chem. Sci. (2015) 6, 10 5473
a=9.769(5)Å b=13.318(5)Å c=17.543(5)Å
α=90.000(5)° β=103.191(5)° γ=90.000(5)°
C40H68N8O13
C40H68N8O13
Chem. Sci. (2015) 6, 10 5473
a=13.3658(2)Å b=9.48640(10)Å c=17.7634(2)Å
α=90° β=104.2040(10)° γ=90°
C36H52N8O9
C36H52N8O9
Chem. Sci. (2015) 6, 10 5473
a=16.9971(11)Å b=9.2681(4)Å c=25.8496(17)Å
α=90° β=99.408(6)° γ=90°
31
C23H30F3N3O,2(C2F3O2)
RSC Medicinal Chemistry (2020)
a=8.23301(6)Å b=13.02347(14)Å c=13.57687(16)Å
α=98.1817(9)° β=92.5946(8)° γ=103.5389(8)°
19
C20H32N3O2,C2F3O2,1.65(H2O)
RSC Medicinal Chemistry (2020)
a=17.41370(10)Å b=8.14510(10)Å c=33.6364(2)Å
α=90° β=90.4130(10)° γ=90°
Cis-22a
C22H29N3
RSC Medicinal Chemistry (2020)
a=7.2232(3)Å b=8.9059(4)Å c=15.2815(6)Å
α=96.464(3)° β=95.779(3)° γ=99.987(4)°
9
C24H34N2O2,2(C2F3O2)
RSC Medicinal Chemistry (2020)
a=12.18020(10)Å b=16.45030(10)Å c=14.08290(10)Å
α=90° β=93.2560(10)° γ=90°
40
C23H29F3N3O2,C2F3O2,C4H10O
RSC Medicinal Chemistry (2020)
a=15.6425(3)Å b=12.7231(2)Å c=16.3931(3)Å
α=90° β=106.097(2)° γ=90°
6-methyl-2-(3-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)pyrimidin-4(3H)-one
C13H16N4O
RSC Medicinal Chemistry (2020)
a=8.1640(3)Å b=8.5511(4)Å c=19.8770(7)Å
α=93.396(3)° β=99.154(3)° γ=117.195(4)°
2-(3-ethyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)-6-methylpyrimidin-4(3H)-one
C14H18N4O
RSC Medicinal Chemistry (2020)
a=18.8002(2)Å b=9.62410(10)Å c=14.3730(2)Å
α=90° β=90° γ=90°
6-ethyl-4-hydroxy-2-(3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)pyrimidin-1-ium
Cl,C10H13N4O2,H2O
RSC Medicinal Chemistry (2020)
a=8.66205(5)Å b=14.39226(6)Å c=9.94738(4)Å
α=90° β=90.8062(4)° γ=90°
(1SR,2SR,4SR)-7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid
C7H8O3
Acta Crystallographica Section E (2004) 60, 3 o381-o382
a=5.239(4)Å b=23.709(19)Å c=5.669(5)Å
α=90.00° β=111.708(13)° γ=90.00°